ESMO 2024: Treatment of uHCC - Episode 17

Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

, , , , ,

Panelists discuss how ongoing trials and investigational agents, including the Checkmate 9DW study, could significantly influence future treatment approaches for unresectable hepatocellular carcinoma .

Video content above is prompted by the following:

Dr Finn to group (Iif time allows): Are there other trials or investigational agents that for which you are waiting for updates that could potentially impact affect how unresectable hepatocellular carcinoma uHCC is treated?

• Any additional thoughts on findings from Checkmate 9DW?